Diversified Trust Co Boosts Holdings in AbbVie Inc. $ABBV

Diversified Trust Co grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 23.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 57,076 shares of the company’s stock after purchasing an additional 10,891 shares during the period. Diversified Trust Co’s holdings in AbbVie were worth $13,215,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie during the 2nd quarter worth approximately $25,000. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie during the second quarter valued at approximately $26,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie in the second quarter worth $28,000. Financial Gravity Companies Inc. bought a new position in AbbVie in the second quarter worth $36,000. Finally, Delos Wealth Advisors LLC purchased a new position in AbbVie during the second quarter valued at $39,000. 70.23% of the stock is owned by institutional investors.

AbbVie Price Performance

Shares of NYSE ABBV opened at $229.63 on Wednesday. The firm has a market cap of $405.84 billion, a P/E ratio of 173.96, a PEG ratio of 1.31 and a beta of 0.36. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The company has a 50 day moving average of $226.67 and a 200 day moving average of $213.27.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.0%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is currently 496.97%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ABBV shares. Scotiabank started coverage on shares of AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price on the stock. Bank of America upped their price objective on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Wells Fargo & Company lifted their target price on shares of AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Morgan Stanley upped their price target on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Finally, JPMorgan Chase & Co. lifted their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.